Boneu B, Bouissou F, Abbal M, Sie P, Caranobe C, Barthe P
Thromb Haemost. 1981 Oct;46(3):623-5.
In order to compare the plasmatic progressive antithrombin activity to the concentration of three thrombin inhibitors, antithrombin III (AT III), alpha 2 macroglobulin (alpha 2 M), alpha 1 anti-trypsin (alpha 1, AT) in nephrotic syndrome, a prospective study was carried out on a group of 28 children affected with the disease. A dramatic reduction of the level of AT III and of alpha 1 AT, two inhibitors of molecular weight close to that of albumin, was observed. The decreased level of AT III was counterbalanced by an increase in alpha 2 M. This phenomenon accounts for the increased progressive antithrombin activity observed in all the affected children. It is suggested that the above compensatory mechanism explains the absence of thrombotic accidents in this series and that the benefit of heparin therapy is doubtful in these conditions.
为比较肾病综合征患者血浆中三种凝血酶抑制剂（抗凝血酶III（AT III）、α2巨球蛋白（α2 M）、α1抗胰蛋白酶（α1，AT））的浓度与血浆中进行性抗凝血酶活性，对一组28名患该病的儿童进行了一项前瞻性研究。观察到分子量与白蛋白相近的两种抑制剂AT III和α1 AT的水平显著降低。α2 M的增加抵消了AT III水平的降低。这一现象解释了在所有患病儿童中观察到的进行性抗凝血酶活性增加。有人提出，上述代偿机制解释了该系列中无血栓形成事件的原因，并且在这些情况下肝素治疗的益处值得怀疑。
